Our findings suggest that MTHFD2 inhibited mitochondrial respiration and impacted the UPR in MM cells, so we hypothesized that targeting MTHFD2 may be useful in combination with Btz for the treatment of MM. Here, MTHFD2 is linked to Miyoshi myopathy.